The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of IV topotecan versus CRLX101 in the second-line treatment of recurrent extensive-stage small cell lung cancer (ES-SCLC).
Thomas A. Hensing
No relevant relationships to disclose
Theodore Karrison
No relevant relationships to disclose
Edward Graeme Garmey
Employment or Leadership Position - Cerulean Pharma
Stock Ownership - Cerulean Pharma
Meliessa G. Hennessy
Employment or Leadership Position - Cerulean Pharma
Stock Ownership - Cerulean Pharma
Ravi Salgia
No relevant relationships to disclose